Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer.

Head & Neck
Dario PasalicQuynh-Nhu Nguyen

Abstract

Metastatic head and neck cancers (HNCs) predominantly affect the lungs and have a two-year overall survival (OS) of 15% to 50%, if amenable for pulmonary metastasectomy. Retrospective review of the two-year local control (LC), local-regional control (LRC) within the same lobe, OS, and toxicity rates in consecutive patients with metastatic pulmonary HNC who underwent stereotactic ablative radiotherapy (SABR) January 2007 to May 2018. Evaluated 82 patients with 107 lung lesions, most commonly squamous cell carcinoma (SCC; 64%). Median follow-up was 20 months (range: 9.0-97.6). Systemic therapy administered in 34%. LC, LRC, and OS rates were 94%, 90%, and 62%. Patients with oligometastatic disease had a higher OS than polymetastatic disease, 72% vs 44% (HR = 0.30, 95% CI: 0.14-0.64; P = .008). OS in oligometastatic non-SCC and SCC were 100% and 66% (P = .03). There were no grade ≥3 toxicities. Metastatic pulmonary HNCs after SABR have a two-year OS rate comparable to pulmonary metastasectomy.

References

Jul 1, 1987·Archives of Otolaryngology--head & Neck Surgery·P Zbären, W Lehmann
Oct 1, 1987·American Journal of Surgery·C KotwallD P Shedd
Jan 1, 1997·The Journal of Thoracic and Cardiovascular Surgery·U PastorinoUNKNOWN International Registry of Lung Metastases
Sep 24, 1999·Annals of Surgical Oncology·D LiuR J Ginsberg
Mar 6, 2008·Archives of Pathology & Laboratory Medicine·Jaishree Jagirdar
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Aug 25, 2009·The Annals of Thoracic Surgery·Satoshi ShionoUNKNOWN Metastatic Lung Tumor Study Group of Japan
Jul 24, 2010·AJR. American Journal of Roentgenology·Mizuki NishinoAnnick D Van den Abbeele
Sep 21, 2010·European Annals of Otorhinolaryngology, Head and Neck Diseases·D DequanterP Lothaire
Mar 23, 2011·Nature Reviews. Clinical Oncology·Ralph R Weichselbaum, Samuel Hellman
Dec 17, 2011·International Journal of Radiation Oncology, Biology, Physics·Michael T MilanoPaul Okunieff
Dec 17, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Joe Y ChangUNKNOWN IASLC Advanced Radiation Technology Committee
Apr 1, 2017·JAMA : the Journal of the American Medical Association·Hyeyeun LimCari M Kitahara
Jun 27, 2017·Head & Neck·Fréderic DuprezMarc Mareel
Aug 2, 2017·ESMO Open·Alexia VogtAurelius Omlin
Dec 15, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Piet OstGert De Meerleer
Apr 27, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph E TotaAnil K Chaturvedi
May 9, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel R GomezJohn V Heymach
Aug 1, 2019·The Lancet Oncology·Sean P PitrodaRalph R Weichselbaum
Oct 3, 2019·The New England Journal of Medicine·H Gilbert WelchWilliam C Black

❮ Previous
Next ❯

Citations

Oct 13, 2020·The Laryngoscope·Aurora G VincentYadranko Ducic
Dec 16, 2020·Critical Reviews in Oncology/hematology·Thiago Bueno OliveiraPaolo Bossi
Jan 21, 2021·Journal of Cancer Research and Clinical Oncology·Ciro FranzeseM Scorsetti
Jan 9, 2021·Frontiers in Oncology·Petr SzturzJan B Vermorken
Feb 27, 2021·ANZ Journal of Surgery·Norhafiza Mat LazimJonathan Clark
Apr 12, 2021·The Journal of Thoracic and Cardiovascular Surgery·Mara B AntonoffQuynh-Nhu Nguyen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.